Nonacus
Liquid biopsy NGS panels and kits for cancer detection and monitoring, sold to clinical labs, hospitals and researchers
Highlights
- New on EvolcAdded 2026-10-31
About Nonacus
Nonacus develops liquid biopsy and next-generation sequencing (NGS) products for cancer detection, monitoring and treatment decisions. Its GALEAS range includes GALEAS Bladder, GALEAS Tumor and GALEAS Hereditary Plus, alongside cell-free DNA extraction kits, library preparation kits and custom targeted panels built on its Cell3 Target enrichment system.
Customers include clinical laboratories, clinicians, hospitals and clinical and translational researchers. The company sells panels, kits and accredited clinical testing services; Informed Genomics, its UKAS-accredited clinical services line, began trading as Nonacus Clinical Services in May 2025. Its non-invasive bladder cancer test is offered by the NHS and by independent hospitals in the UK.
Nonacus was founded in 2015 by Chris Sale and Lee Silcock and is headquartered in Birmingham, UK, where it moved into purpose-built offices and a laboratory in 2022. Jeff Bousfield is Chief Executive Officer.
Product: GALEAS Bladder, Tumor and Hereditary Plus panels, cfDNA extraction kits, custom NGS panels (Cell3 Target) and accredited clinical testing services.
Jobs at Nonacus
Leadership
- Chris Sale · Chief Strategy Officer and Co-founderSource: company website
- Jeff Bousfield · Chief Executive officerSource: company website
- Lee Silcock · Chief Product Officer and Co-founderSource: company website
- Simon Davis · Chief Commercial OfficerSource: company website
- Samuel Clokie · Director of Bioinformatics, Data Science & SoftwareSource: company website
More biotech & pharma companies
Norgine
Specialist pharmaceutical company acquiring, developing and commercialising medicines for gastroenterology and other therapy areas in EuropeNorthumbria Pharma
Develops and supplies pharmaceutical products and licensing, regulatory and safety services for healthcare and pharmaceutical partnersNew on EvolcNovabiotics
Clinical-stage biotech with cysteamine drug candidates and a nail-care product sold through UK podiatristsNew on EvolcNovogaia
AI-driven drug discovery company developing medicines from fungi for unmet medical needsNovumgen
Develops and licenses medicines and finished formulations for pharma partners in oncology, immunology and rare diseasesNew on EvolcNRG Therapeutics
Develops oral medicines for ALS, Parkinson’s and other neurodegenerative diseasesNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- Complianz
- Google Tag Manager
- HubSpot
- WordPress
- jQuery